Cambridge Healthtech Institute’s Inaugural

Process Optimisation for Precision Fermentation

Upstream and Downstream Production Strategies for Scale Up and Cost Reduction

20 - 21 March 2024 ALL TIMES CET

We have added a new Alternative Protein Production stream to Bioprocessing Summit Europe to recognize the synergy between the manufacturing technologies used for these nascent food products and biologic drugs. This meeting provides an opportunity for these communities to share best practices and explore prospects for collaborations and technology innovations. The second 1.5-day program, Process Optimisation for Precision Fermentation, considers the role of target product profiles in strain development, strategies for increasing yield and reducing costs in upstream processing, adaptations of chromatography technologies for downstream processing, and new approaches to ensuring product quality. The program also includes a special session on new developments in mycoprotein fermentation. Speakers and delegates participating in this track are welcome to attend talks in the six other programming streams at the event.

Wednesday, 20 March

Registration Open10:30

PLENARY KEYNOTE SESSION

BACK TO THE FUTURE OF BIOPROCESSING—ANTIBODIES TO EXTRACELLULAR VESICLES

11:15

Chairperson's Opening Remarks

Alois Jungbauer, PhD, Professor & Head, Biotechnology, Institute of Bioprocess Science and Engineering, University of Natural Resources and Life Sciences (BOKU)

11:20 PLENARY PRESENTATION:

What Have Monoclonal Antibodies Ever Done for Us? Past, Present, and Future Perspectives on Antibodies and How They Have Driven Bioprocessing Progress

Paul Varley, PhD, Senior Vice President, Development, Alchemab Therapeutics

Advances in bioprocessing have been pivotal to the emergence of monoclonal antibodies as one of the most successful classes of drugs in modern medicine. In this talk we will consider this journey and ask what's next for antibodies. We will also explore how advances in antibody bioprocessing continue to enable the next generation of biological medicines through the emergence of new product modalities.

11:50 PLENARY PRESENTATION:

Extracellular Vesicles as Promising Drug Modalities in Spinal Cord Injury and Other (Neuro-)Degenerative Diseases

Eva Rohde, MD, Chair, Transfusion Medicine, Director GMP Unit, Spinal Cord Injury and Tissue Regeneration Center Salzburg (SCI-TReCS), Paracelsus Medical University Salzburg

Extracellular vesicles (EVs) have emerged as promising new biologic drug modalities. EV therapeutics (EV-Tx) from mesenchymal stromal cells (MSC) exert anti-inflammatory, anti-fibrotic and regenerative effects. MSC-EV-Tx could optimise healing after acute traumatic injury. Challenges in reproducible EV-Tx manufacturing prevent comprehensive evaluation of their efficacy. In early research, the paradigm of “the-process-is-the-product” is valid for complex biologicals. A “one-size-fits-all” approach to solve technical and regulatory issues is not available for EV-Tx. The claimed disease-related mechanisms of action (MoA) of candidate EV-Tx will determine regulatory requirements to be met. This presentation will introduce concepts to accelerate EV-Tx testing in various target diseases.

Session Break12:20

Sponsored Presentation (Opportunity Available)12:35

Networking Lunch (Sponsored Opportunity Available)13:05

UPSTREAM PRODUCTION

14:15

Chairperson’s Remarks

Seren Kell, Senior Science and Technology Manager, The Good Food Institute Europe

14:20

KEYNOTE PRESENTATION: Rational Strain Engineering for Precision Fermentation

John Morrissey, PhD, Professor, Microbiology, University College Cork

Precision fermentation deploys engineered microbes to produce desired biochemicals and proteins. Although the use of microbes in industrial fermentations is not novel, the advent of new molecular techniques to precisely repurpose microbial pathways and processes has shifted paradigms. Using methods such as CRISPR, genome engineering, and Golden Gate in vitro DNA assembly, it is now possible to rapidly construct tailored microbial strains to use in novel fermentative bioprocesses. Some of the most significant advances have been made with traditional and novel yeast species, where there are now multiple examples of strains engineered to produce alternative proteins, speciality lipids, and flavours.

14:50

Beyond Temperature Control: How to Enable Advanced Control of Precision Fermentation to Achieve Your High Titres

Nadav Bar, PhD, Professor, Chemical Engineering, Norwegian University of Science and Technology

Precision fermentation reaches beyond genetics, aiming for high peptide and compound yields. This lecture explores evolving bioprocessing control techniques, from basic temperature and pH control to advanced methods like multivariate cascade control, model predictive control, and reinforcement learning. Achieving precision depends on accurate bioprocess modeling, addressing imprecise measurements, reducing process noise, and model uncertainty. We introduce bioprocess estimators, coupled with machine learning, for better control and enhanced data analysis. Real-world case studies from Trondheim, Norway's Microbial Feedback Control Laboratory, reveal precise control in aerobic precision fermentation, providing practical insights.

15:20

Lessons Learned from Pharmaceutical Bioprocessing Combined with Essential Ingredients to Achieve Cost Parity with Vegan Cheese

Christoph Herwig, PhD, former Professor, Bioprocess Engineering, Vienna University of Technology; CPO, Fermify GmbH; Senior Scientific Advisor, Körber Pharma Austria

Biopharmaceutical recombinant proteins need to be competitive in the Euro/g range; for novel food we need to target Euro/kg. This contribution shows the main ingredients for a disruptive step towards achieving cost parity for recombinantly produced casein for vegan cheese. The main enablers are robust continuous microbial biomanufacturing controlled by feedback digital twins for individual unit operations and along the complete process chain.

15:50 Navigating the Challenges of Alternative Protein Production : Explore the Role of Culture Media Optimization

Benoît Drogue, PhD, Global Innovation Manager, Global Innovation, Procelys by Lesaffre

Given the increasing traction in alternative protein produced by precision fermentation, improving the process efficiency will be crucial for accelerating time-to-market and competitiveness.  The optimization of culture media leads to significant improvements in protein quantity and quality, spanning from upstream to downstream processing. We will see how a strategic approach to culture media optimization could help organizations unlock the power of recombinant protein production.

Refreshment Break in the Exhibit Hall with Poster Viewing16:20

17:00

FEATURED PRESENTATION: Scaling-Up New Technologies: The Engineer's Perspective

Joachim Schulze, PhD, CTO, Planetary Group

New bioprocesses are started in the laboratory—under laboratory conditions. Downstream is often undervalued—the upstream is the focus. Okay for the start, but we need to understand the complete process with the appropriate DSP technologies to calculate CAPEX and OPEX. This is needed to evaluate the feasibility of the technology. A TEA (techno-economical analysis) in early-stage, including sensitivity analysis, shows potential weaknesses and will control the R&D. Guidelines of a practitioner will be discussed in the presentation.

17:30

Unleashing the Power of CO2-Fixation for Proteinogenic Amino Acid Production

Justin Smith, Chief Technology Officer, Arkeon Bio

Greenhouse gas emissions to the atmosphere, including anthropogenic released CO2, are major contributors to the accelerating climate crisis. A promising technology for carbon capture and utilisation (CCU) of CO2 is gas fermentation. Methanogenic archaea possess metabolic characteristics, such as high CO2 uptake rates, which makes them advantageous in different biotechnological applications. Methanothermobacter sp. strain Arkeon is able to convert CO2 into proteinogenic amino acids and excrete them to the supernatant.

INTERACTIVE BREAKOUT DISCUSSIONS

18:00Interactive Breakout Discussions

Interactive Breakout Discussions are informal, moderated discussions, allowing participants to exchange ideas and experiences and develop future collaborations around a focused topic. Each discussion will be led by a facilitator who keeps the discussion on track and the group engaged. To get the most out of this format, please come prepared to share examples from your work, be a part of a collective, problem-solving session, and participate in active idea sharing. Please visit the Interactive Breakout Discussions page on the conference website for a complete listing of topics and descriptions.

IN-PERSON ONLY BREAKOUT:

Essential Ingredients for Economic Precision Fermentation Solutions

Christoph Herwig, PhD, former Professor, Bioprocess Engineering, Vienna University of Technology; CPO, Fermify GmbH; Senior Scientific Advisor, Körber Pharma Austria

  • What is precision fermentation compared to recombinant protein production of biopharmaceuticals?
  • How to achieve the drastically different unit economics?
  • What is the role of digital transformation and digital twins?
  • What can the biopharma sector learn from precision fermentation?​

Close of Day18:30

Thursday, 21 March

Registration and Morning Coffee08:00

SCALE-UP STRATEGIES

08:55 Chairperson's Remarks

Giovanni Campolongo, Senior Market Segment Manager, Process Analytics, Hamilton Bonaduz AG

09:00

Optimisation Strategies for Downstream Processing

Johannes Felix Buyel, PhD, Head, Institute for Biochemical Engineering, University of Natural Resources and Life Sciences (BOKU)

The term optimisation is vague and requires contextualization. In terms of bioprocesses, optimization typically refers to a cost reduction, i.e., fewer € per kg of product, which can be achieved through an increase in volumetric productivity (e.g., faster operation), more cost-efficient equipment or a reduction in consumables. In addition, there are also “soft” optimisation goals, such as improved product safety and, especially in light of climate change and resource depletion, a reduced ecologic/environmental footprint. Here, we will discuss implications of these optimisation goals in the context of precision fermentation focusing on technology fit, scalability, and adaptability of unit operations.

09:30

Challenges in Upscaling New Technologies

Gero Grieve, Head, Project Development, ERIDIA GmbH

To be successful in biotechnological development, several challenges must be overcome and practical solutions implemented. Starting from the definition of the end product of the process and the existing equipment, an optimised upstream and downstream process must be defined in the early phase of process development and integrated into the laboratory activities.

10:00

Strategies to Scale-Up Capacity for Long-Term Category Growth

Dominic Silvester, Senior Consultant, Integration Consulting

Alternative protein companies encounter numerous manufacturing-related challenges when seeking to utilise precision fermentation—from initial strain development to executing large-scale commercial production. Ensuring long-term category growth rests upon mapping, understanding, and developing strategies to effectively address these challenges in economically viable ways. This talk introduces key hurdles encountered at different product development stages, provides an overview of existing production capacity, and highlights strategies being employed to overcome capacity constraints.

Coffee Break in the Exhibit Hall with Poster Viewing10:30

11:00

Computational Fluid Dynamics (CFD) for Designing Bioprocess Scale-Up

Cees Haringa, PhD, Assistant Professor, TU Delft

Local environmental conditions may have considerable impact on cellular—and consequently—bioprocess performance. Using computational fluid dynamics (CFD) combined with biokinetic models allows study of this impact. We utilize agent-based modelling to study bioprocesses from the cellular perspective, study how cells observe variations in their environment, and how this can be translated to representative downscaling experiments to unravel the impact on process performance. I will outline recent developments regarding this approach, and discuss how we combine it with other expertise in the bioprocess engineering section for integrated development and scale-up of bioprocesses. 

11:30

Precision Fermentation—From Strain Development to Production at-Scale

Reza Ranjbar, PhD, Head of Technology Strategy—Biotechnology, CPI

Precision fermentation offers a compelling alternative to animal-derived proteins and fats and alternatives to sugar, synthetic colourants, and preservatives—aligning with sustainability and ethics. Over 200 companies are active in the field, yet commercial viability remains a challenge, necessitating process improvement and cost reduction. This talk addresses pivotal decisions: selecting efficient hosts, optimising fermentation process from small-scale to industrial-scale, and employing scale-down approaches for a seamless scale-up process.

12:00

Engineering Enzymes for the Food Industry

Claes Gustafsson, PhD, Chief Commercial Officer & Co-Founder, ATUM

Enzymes are used across the food industry, from dairy to carbohydrate manufacturing, baking, brewing, and much more. The last decade has seen an explosion in new engineered biocatalysts designed to improve food manufacturing. This presentation will present case studies where ATUM's ProteinGPS platform has provided novel enzymes for the food industry. As technology advances, the use of these enzymes in food production is poised to grow, offering a promising future for the industry.


Networking Lunch (Sponsorship Opportunity Available)12:30

PROCESS SYSTEM ENGINEERING

13:45

Chairperson's Remarks

Gero Grieve, Head, Project Development, ERIDIA GmbH

13:50

Fermentation Process Monitoring and Optimisation Using Soft Sensors

Ram Uritski, PhD, Vice President, Bioprocess, Remilk

Soft sensors are an emerging technology that helps optimise bioprocesses by providing real-time data on key process variables, predictive analytics, and fault detection. Remilk uses soft sensors to monitor and optimise its fermentation processes, resulting in significant improvements in R&D throughput, product quality, and cost-effectiveness. This presentation will discuss the use of soft sensors for predictive bioprocess optimisation and will provide the latest advances in soft sensor technology.

14:20

Navigating the Interface between Bio and Food Technology

Aditya Shah, MSc, Co-Founder, Nayamylk Products

Alternative proteins are used in food-related applications. Therefore, there are three fundamental differences between alternative proteins and proteins manufactured for the traditional pharma or enzyme industry: (1) taste reigns supreme; (2) costs need to be significantly lower; and (3) food safety regulations need to be followed. Considering this, the presentation will focus on how best to approach process systems engineering by optimising strategies available from the food and bioprocess industries.

Close of Precision Fermentation Track14:50